INTRODUCTION
As well as causing of distress, depression in Parkinson's disease has been associated with greater functional disability,[1] rate of physical and cognitive decline,[2] dementia risk, [3] and mortality, [4] and reduced quality of life. [5] Anxiety is also a prominent feature of PD [6;7] although implications for outcome are less well understood. Evidence for the efficacy of pharmacotherapy remains weak and often inconsistent, [8;9] although there is a growing number of trials of pharmacological and psychological interventions for depression (e.g. see http://ClinicalTrials.Gov). Trials are needed in PD anxiety although there is some evidence that anxiety symptoms improve in depressed PD patients treated with the SSRI citalopram. [10] . Although depression and anxiety symptoms can occur in isolation in PD, they frequently co-exist. [11;12] While some have suggested that this reflects the co-morbidity of distinct pathophysiological substrates, [11] others argue that anxious-depression represents a specific and common depressive subtype in PD. [7] The relationship between depression and anxiety has important implications for treatment and clinical trials. Non-PD patients with Major Depression (MD) with marked anxiety (anxious-depression) show poorer outcomes than those with MD alone when treated with SSRI's and when switched/augmented with other agents. [13] If anxious-depression is common in PD, similar reduced treatment efficacy may be anticipated, while combining subtypes could produce aggregate results that do not adequately inform the response to treatment of either subgroup.
Broader clinical heterogeneity of PD has been examined using empirical approaches such as cluster analysis (CA) or latent class analysis (LCA). [14] In contrast to pre-specified clinical or theoretically defined subgroups, data-driven methods seek to identify clusters of patients defined by low intra-group but high inter-group differences across a set of selected variables. Applying similar methods to depression and anxiety related symptoms may identify empirical subgroups that then become available for validation and further study. Differences in pathophysiology and other factors involved in symptom onset and maintenance could guide the development of more targeted treatment. The present study describes the first use of a data-driven approach to explore possible heterogeneity in depressive and anxiety-related symptoms in patients with PD. 
METHODS

Eligibility and recruitment
Patients were recruited over a 12-month period from specialist PD or movement disorder outpatient clinics (Ethics ref 07/MRE01/9) as part of a longitudinal study (PROMS-PD) (UKCRN ID 2519).
Inclusion criteria were a clinical diagnosis of idiopathic PD, [15] the ability to provide informed consent at entry into the study, and living within two hours travel time of a study research centre. Exclusion criteria were the presence of sensory loss or communication difficulty (including inadequate command of English) sufficient to interfere with assessment. Patients with cognitive impairment or severe psychiatric disorder were excluded only if these interfered with the capacity to consent. The eligibility criteria were deliberately chosen to include as broad a range of patients as possible in terms of age and clinical severity.
Assessments
Participants were assessed over two sessions, typically in their own home. Where possible patients were assessed in their motor 'on' state. Depressive, anxiety and related symptoms were assessed using a semistructured interview based on the Geriatric Mental State (GMS), [16] an instrument designed to assess psychopathology in older adults including those with significant cognitive impairment. Items were rated 0=absent or 'normal'; 1=present but not prominent (mild to moderate intensity, infrequent or fleeting), 2=prominent (severe, frequent or persistent). Symptoms were rated as reported or observed.
[17] Selfreported depression and anxiety was assessed using the Hospital Anxiety and Depression Scale (HADS), [18] Annual assessments are planned for up to 4 years.
Statistical analysis
Latent Class Analysis (LCA) can identify unobserved (latent) subgroups of cases that share similar symptoms from a set of multivariate categorical data. Model-based CA methods such as LCA avoid a criticism of conventional heuristic CA approaches such as linkage that do not provide a formal basis for PAGE 6 determining the optimal number of clusters or indeed the existence of more than a single cluster. LCA provides inferences for statistically comparing the fit of solutions across different numbers of clusters, and is also better able to handle missing data. We employed LCA of binary symptom variables using M-Plus software.
[25] Subjects were allocated to classes based on the maximum estimate of a posteriori probability of cluster membership (Maximized Allocation Probability method). Individual GMS symptoms were dichotomized as 'prominent' (score=2), or 'absent or present but not prominent' (score<2), to provide a classification based on the presentation of symptoms with clear clinical significance. Symptoms with a frequency of less than 2% (N<10) were excluded. In total 28 items were identified as relevant to phenotyping (see fig 1) . Approximately 30% of participants showed evidence of significant cognitive impairment on the ACE-R.
On the HADS 13% reported marked depressive symptomatology and 22% anxiety. Mild to moderate symptoms (HADS subscale score 8-10) were reported in a further 22% and 23% respectively. Almost all (94.9%) were taking antiparkinsonian drugs, and 24% reported taking antidepressant and/or anxiolytic medication. PAGE 7 Figure 1 shows the ranked profile of 28 GMS items. The most frequent prominent symptoms were worry (33.5%), subjective tension and restlessness (33.2%) and fatigue (27.6%). Symptoms such as excessive energy, belief about punishment and suicidal thinking were rare (<2%, data not shown) and not included in the LCA.
Empirically defined patient subgroups
Seven LCA solutions were evaluated, with a 4-class solution providing the best overall fit across a range of information indices (table 2). The median allocation probability was 99% with 90% of the sample allocated to their final class with a probability of 80% or more. The largest class (class 4) included 59.4% of the sample, class 3 22%, and classes 1 and 2 8.9% and 9.0% respectively.
Interpreting classes from cluster-based methods is a largely non-empirical process and involves visually identifying those features which most clearly (a) define an individual class and (b) distinguish it from other classes. Figure 2a and 2b shows the symptom probability profiles for the 28 variables for each of the individual class. Features of classes 1 and 2 were sad and/or empty mood, loss of interest, slow thinking, loss of confidence, lack of energy and poor concentration. In contrast, loss of enjoyment was rare and symptoms of hopelessness, worthlessness and guilt relatively uncommon, particularly in class 2. In addition, and in contrast to class 2, patients in class 1 also showed high probabilities of prominent worry and tension/restlessness, irritability, general anxiety/panic, specific fear and autonomic symptoms of anxiety. Class 3 was marked by a profile of prominent worry and tension/restlessness, and moderate probabilities of other severe anxiety-related symptoms but with a low probability of depressive symptomatology. Finally, class 4 was characterized by overall low probability of prominent symptoms. Table 3 shows the main demographic and clinical characteristics of the 4 classes. All variables showed highly significant differences (P < 0.001) including when age was used as a covariate. Patients in class 4 tended to be older, with a high proportion of males, later age at onset and shorter disease duration, with lower levels of motor symptoms, disability and medication. Non-tremor symptoms were least common in this class. Class 2 was a similar to class 4 in terms of age, age of onset, duration of PD and level of medication, but showed more cognitive and motor impairment and disability, and somewhat higher levels HADS depression and anxiety. This class also displayed the most pronounced non-tremor dominant symptom profile. Classes 1 and 3 were the youngest with more advanced disease and higher mean levels of antiparkinsonian medication than classes 2 and 4. Class 1 in particular showed early mean age of onset and long disease duration. Class 1 patients also showed greater disability and twice the level of significant cognitive impairment than class 3, and markedly increased levels and rates of anxiety and depression.
Predictors of class membership
Class membership was assessed using multinomial logistic regression with a set of dichotomised demographic and clinical variables: age (<70/≥70 years), gender (female/male), age at diagnosis (<55/≥55 years), PD duration (<5/≥5 years), levodopa equivalent daily dose (LEDD) (<600/≥600mg/day), Schwab and England (<80/≥80), UPDRS III (<23/≥23), ACE-R (<83/≥83). Class 4 was the reference category.
Duration of PD did not independently predict class membership in any model and was therefore not included in the final analysis.
Relative to class 4, membership of class 1 was significantly (P<0.05) predicted by younger age (Odds Ratio (OR)=2.6, 95% confidence interval=1.0-6.6), PD onset less than 55 years (OR=3.9, 1.6-9.3), greater level of disability (Schwab and England) (OR=2.6, 1.2-6.0) and higher UPDRS III score (OR=2.4, 1.0-5.5). Female gender approached but did not reach significance (P<0.10). Membership of class 3 was predicted by a similar set of variables: younger age (OR=2.2, 1.2-4.0), female gender (OR=3.0, 1.8-4.8),
younger age of PD onset (OR=1.7, 1.0-3.1), higher LEDD (OR=1.8, 1.1-2.9) and greater disability (OR=2.3, 1.3-4.1). Only cognitive impairment significantly predicted membership of class 2 (OR=3.7, 1.8-7.7). 1<234, 3<24
• Duration (Years) 9.6 (8.2) 7.6 (6.2) 7.7 (6.1) 6.1 (5.4) 1>4
• UPDRS-III (Total score) 33.0 (14.6) 30.5 (10.6) 27.0 (10.9) 24.9 (11.7)
1>34, 2>4
• Tremor/non-tremor ratio 0. • LED (mg/day) 1129 (1171) 728 (439) 1017 (763) 694 (608) 1>24,3>4
Cognitive function Cluster-based methods are subject to a variety of methodological factors that can influence the robustness and therefore potential validity of the solutions. As noted, LCA has advantages over traditional CA methods in providing a range of indices to inform decisions about the optimal number of clusters. The present results strongly supported a 4-class solution over one with more or fewer subgroups. The high allocation probabilities further suggest that patients were assigned unequivocally to one of the 4 classes.
Ideally, we would have liked to replicate the classification in an independent sample to further confirm its reliability, as done in one similar study using cluster analysis.
[30] Unfortunately, our sample size, although large, was insufficient given the number of parameter estimates being modelled (N=115).
Face validity was high and the subgroups clinically interpretable. Validity was further supported by the associations of the classes with a range of variable not included in the LCA. These converged on evidence from previous studies describing associations between depression and broad clinical and motor phenotypes. Our results support a link between psychopathology and non-tremor dominant motor phenotype, with the 'Healthy' subgroup showed the highest proportion of tremor symptoms and the 'Apathetic-depressed' group the least. Younger age of onset emerged as a distinguishing feature in class 3 but particularly in class 1, along with female gender and higher LEDD. However, unlike the apparently benign psychiatric profile of the 'Young onset' groups of some previous studies[22;28] younger age of onset in the present study was associated with marked anxiety (classes 1 and 3). The present study also suggests that at least some patients with younger onset (class 1) experience significant depressive symptomatology, particularly those with longer duration, advanced disease and greater disability, similar to a previous report. [29] An important question is whether subtypes remain stable or patients move between subtypes. Pending longitudinal study, a partial answer can be found in evidence on the duration of the individual symptoms PAGE 14 that define class membership (see supplementary information). Almost all prominent symptoms reported had been present for most days in the past 6 months in over 80% of patients, and for many, most days in the past 2 years. Although not proving that the subtypes are stable, it suggests that that the symptoms on which they are based are persistent in this sample.
A criticism of cross-sectional studies is that empirically distinct clusters may simply reflect observations of patients at different stages of a homogenous but progressive disease.
[14] A number of facts suggest that this is not the case with the present findings. The between-group differences were modest compared to the range observed within the classes, with the 'Anxious' and 'Depressed' subgroups showing almost identical mean disease durations and levels of disability. Also, the logistic regression analysis failed to indicate a role of disease duration in predicting subtype. In contrast, age of onset emerged as a more significant influence, with younger onset (independent of duration) associated with the two anxiety-related subtypes.
The high level of anxiety-related symptomatology in this sample, and specifically in two of the subgroups, is consistent with emerging evidence.[6;7;33] Even when sub-syndromal, GAD-like symptoms of subjective tension, worry and irritability can be a significant source of distress, particularly if chronic, but may be missed without adequate screening. Anxiety-related symptoms are a common feature of depressive disorder although the depressive symptoms are generally held to be primary and the target of treatment. However, anxiety symptoms may turn out to have a high prominence in some PD patients with depression, [34] while symptoms such as anhedonia and guilt may be less characteristic with implications for assessment and diagnosis. If anxious-depression is common in PD it would also have important implications for management and outcome. In the elderly, remission rates of co-morbid depression and GAD is only 27% over 3 years compared to 41% for depression and 48% for GAD.
[35] In a major trial of citalopram (STAR*D), time to remission was longer for anxious-depression, remission rates were significantly lower and reported side-effects higher.
[13] The broad phenotypic similarity of patients in classes 1 and 3, suggests that these two subtypes may be closely associated. Longitudinal study will test the hypothesis that persistent GAD-like anxiety symptoms are a risk factor for anxious-depression. If so, then early identification and treatment of the chronic anxiety symptoms such as worry and tension may be indicated.
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Heterogeneity of affective disturbance in PD may have implications for pathophysiology. The present study used convenience sample of outpatient clinic attenders. The rates of significant selfrated depressive (13%) and anxiety-related (22%) symptomatology from the HADS were comparable to that reported in two recent validation studies with figures of 17% and 20%, [39] and 14% and 22%[40] respectively, and with very similar mean scores. However, the purpose of the present study was not to define the prevalence of the subtypes (the absolute values for which should be treated with caution) but to identify their characteristics and associated features. Studies in different populations may produce different prevalence rates of the 4 subtypes, just as the rate of the 'rapid disease-progression and old ageat-onset' clinical subtype described in other studies has varied from 6 to 64%.
[14] Such variability in prevalence, however, does not challenge the validity of the subtype.
In conclusion, this study suggests that models of depression and anxiety as distinct unitary conditions in PD may be inaccurate. GAD-like anxiety symptoms were amongst the most common in the sample and occurred both independently and in association with significant depressive symptoms. The distinctive 
